Company registration number 08105959 (England and Wales)
IMAAN HEALTHCARE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED
28 OCTOBER 2025
28 October 2025
IMAAN HEALTHCARE LIMITED
COMPANY INFORMATION
Directors
Mr Z A Malik
Mr T Malik
Company number
08105959
Registered office
Unit 2 Micklehead Business Park
St Michaels Road
Lea Green
St Helens
WA9 4YU
Auditor
AMS Audit Limited
1 Hardman Street
Spinningfields
Manchester
M3 3HF
Accountants
AMS Accountants Medical Limited
1 Hardman Street
Spinningfields
Manchester
M3 3HF
IMAAN HEALTHCARE LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 6
Independent auditor's report
7 - 9
Group statement of comprehensive income
10
Group balance sheet
11 - 12
Company balance sheet
13
Group statement of changes in equity
14
Company statement of changes in equity
15
Group statement of cash flows
16
Notes to the financial statements
17 - 41
IMAAN HEALTHCARE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 28 OCTOBER 2025
- 1 -
The directors present the strategic report for the year ended 28 October 2025.
Review of the business
Group turnover for the year was £63,778,807 (2024: £55,665,561) with a profit before tax of £1,585,313 (2024: £1,769,366)
The Board of Directors and Management are continuing with the expansion of the group for the foreseeable future. This expansion will be both acquisition led and through organic growth.
The group is also working with local CCG's to promote additional healthcare services and are committed to ensuring the staff are trained to very high standards.
Principal risks and uncertainties
The principal risks to both the group and company is the potential reduction in NHS income due to government cuts being made, while competition is the main risk to wholesale income.
Key performance indicators
The Key Performance Indicators (KPI's) that the company regard as important are:
a) Gross profit margin
b) The ratio of administrative expenses to turnover
c) The ratio of operating profit to turnover
d) The earnings before interest, tax, depreciation and amortisation
For the period under review the KPI's were as follows:
a) 2025: 33.7% (2024: 33.4%)
b) 2025: 1: 3.16 (2024: 1 : 3.21)
c) 2025: 1 : 42.9 (2024: 1 : 38.7)
d) 2025: £2,925,134 (2024: £2,994,743)
Other information and explanations
The group will continue to pursue opportunities in other sectors to diversify its portfolio and mitigate the risk, it will also be looking to build on its relationships with suppliers to generate a strong supply chain link, which in turn improve efficiency. The group has a strong focus on new efficiency development through core innovation of existing services, introduction of new services and technological advancements which provide a strategic advantage to support future growth.
IMAAN HEALTHCARE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 2 -
Promoting the success of the company
This statement by the Board of Directors describes how they approached their responsibilities under s172(1)(a) to (f) of the Companies Act 2006 in the financial year ending 28 October 2025.
The stakeholders of the company include employees, clients and suppliers of the company.
The directors consider they have acted in good faith to promote the success of the company on behalf of its stakeholders, in relation to the matters set out in s172 of the Act.
The directors monitor and review strategic objectives against long term plans. Regular reviews are held across key business areas, including financial performance, risks and opportunities, health & safety, human resources and operations. The company's performance and progress are reviewed regularly at department, senior leadership and Board meetings.
The fundamental principle in the governance of the company is that of ensuring transparent conduct which reflects fairness in all dealings with employees, clients and suppliers.
The company has a policy of equal opportunities in all aspects of employment. The company's employees are vital to the success of the company. The directors understand that it is critical to engage with and understanding their views and to ensure that all employees' interests are considered. Throughout the company there is consultation at all levels of staff on matters of concern. The consultations evolve to meet the changing needs of the company and are considered valuable by everyone. The policy of the company is to consult and discuss matters with employees and to resolve any problems in accordance with relevant procedures and legislation.
The company's customers and suppliers are fundamental to the success of the company and the company strives to continually improve and strengthen its solution delivery and customer offering for the mutual benefit of all stakeholders.
The company has adopted a policy of only dealing with creditworthy clients. The directors understand the needs for debtor management and so liaises with its clients to minimise any risk of non-payment of debts.
The directors' intentions are to behave responsibly toward all stakeholders and to treat them fairly and equally to ensure everyone benefits from the long-term success of the company.
Environmental matters are taken into consideration by the directors as part of their decision-making process, in order to minimise the company's impact on the environment wherever possible.
The directors have overall responsibility for determining the company's purpose, values and strategy and for ensuring high standards of governance. The primary aim of the directors is to promote a sustainable success for the long-term of the company, generating value for all stakeholders. Throughout the next financial year the directors will continue to review and challenge how the company can improve its engagement with all stakeholders.
Mr Z A Malik
Director
15 October 2026
IMAAN HEALTHCARE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 28 OCTOBER 2025
- 3 -
The directors present their annual report and financial statements for the year ended 28 October 2025.
Principal activities
The principal activity of the group continued to be that of a retail chemist.
Results and dividends
The results for the year are set out on page 10.
Dividends amounting to £761,389 (2024: £819,005) were paid by the group during the year.
No preference dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr Z A Malik
Mr T Malik
Supplier payment policy
The company's current policy concerning the payment of trade creditors is to:
- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.
Financial instruments
Treasury operations and financial instruments
The Group's principal financial instruments comprise cash balances, loans, trade debtors and trade creditors arising from its operations.
The main purpose of these financial instruments is to finance the Group's activities and manage working capital requirements.
The principal financial risks arising from the Group's operations are liquidity risk, credit risk and interest rate risk. The directors review these risks regularly and consider them to be appropriately managed through the Group's financing arrangements and operational procedures.
Liquidity risk
The group seeks to manage financial risk by ensuring liquidity is available to meet foreseeable needs and to invest cash assets safely and profitability. Short-term flexibility is achieved by an invoice discounting facility.
Interest rate risk
The group finances its operations through a combination of retained profits and finance leases and hire purchase contracts. The group exposure to interest rate fluctuations on its borrowings is managed by the use of both fixed and floating facilities.
Foreign currency risk
The group’s principal foreign currency exposures arise from trading with overseas companies. Group policy permits but does not demand that these exposures may be hedged in order to fix the cost in sterling.
IMAAN HEALTHCARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 4 -
Credit risk
The principal credit risk arises from the group’s trade debtors.
All customers who wish to trade on credit terms are subject to credit verification procedures. Trade debtors are monitored on an ongoing basis and provision is made for doubtful debts where necessary.
Disabled persons
Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.
Employee involvement
The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.
Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.
There is no employee share scheme at present, but the directors are considering the introduction of such a scheme as a means of further encouraging the involvement of employees in the company's performance.
Auditor
The auditor, AMS Audit Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.
Energy and carbon report
As the group has consumed more than 40,000 kWh of energy in this reporting period, it is required to report on its emissions, energy consumption or energy efficiency activities.
2025
2024
Energy consumption
kWh
kWh
Aggregate of energy consumption in the year
- Gas combustion
141,413
111,448
- Electricity purchased
511,637
403,224
- Fuel consumed for transport
292,921
360,339
945,971
875,011
IMAAN HEALTHCARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 5 -
2025
2024
Emissions of CO2 equivalent
metric tonnes
metric tonnes
Scope 1 - direct emissions
- Gas combustion
12.44
9.81
- Fuel consumed for owned transport
45.02
35.48
57.46
45.29
Scope 2 - indirect emissions
- Electricity purchased
29.38
25.72
Scope 3 - other indirect emissions
- Fuel consumed for transport not owned by the group
45.44
66.33
Total gross emissions
132.28
137.34
Intensity ratio
Tonnes CO2e per employee
0.2333
0.2543
Quantification and reporting methodology
The group has followed the 2019 HM Government Environmental Reporting Guidelines. The group has also used the GHG Reporting Protocol – Corporate Standard and have used the 2020 UK Government’s Conversion Factors for Company Reporting
Intensity measurement
The chosen intensity measurement ratio is total gross emissions in metric tonnes CO2e per employee, the recommended ratio for the sector.
Measures taken to improve energy efficiency
The company takes very seriously the measurement and mitigation of its environmental impact. It is actively taking steps to reduce its direct and indirect impacts through:
Preferring to use the electric vehicle fleet rather than employee vehicles
Use of media tools for meetings to limit travel requirements
Movement to electronic documentation to reduce its paper use
Installation of smart meters at operating sites to reduce consumption
Awareness campaigns to encourage consumption reduction
The company's scope 1 and 2 consumption and CO2 emissions data has been calculated in line with UK Government environmental reporting guidelines.
Scope 1 consumption and emissions relate to direct combustion of natural gas and fuels utilised for travel and transportation such as company vehicles.
Scope 2 consumption and emissions relate to indirect emissions as a result of the consumption of purchased electricity in its day to day operations.
Statement of directors' responsibilities
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
United Kingdom company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.
IMAAN HEALTHCARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 6 -
In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and parent company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.
On behalf of the board
Mr Z A Malik
Director
15 October 2026
IMAAN HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF IMAAN HEALTHCARE LIMITED
- 7 -
Opinion
We have audited the financial statements of Imaan Healthcare Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 28 October 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the group's and the parent company's affairs as at 28 October 2025 and of the group's profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
The information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
The strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
IMAAN HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF IMAAN HEALTHCARE LIMITED
- 8 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
the parent company financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
We gained an understanding of the legal and regulatory framework applicable to the Group and the industry in which it operates, drawing on our broad sector experience, and considered the risk of acts by Group that were contrary to these laws and regulations, including fraud. We focused on laws and regulations that could give rise to a material misstatement in the financial statements, including, but not limited to, the GPhC, Companies Act 2006, Consumer Rights Act and equivalent local laws and regulations. We made enquiries of management with regards to compliance with the above laws and regulations and corroborated any necessary evidence to relevant information, for example, minutes of the board meetings, legal reports provided to the Group and correspondence between the Group and its solicitors. Audit procedures performed by the engagement team included:
Discussion with management, including consideration of known or suspected instances of noncompliance with laws and regulations and fraud;
Review of financial statement disclosures to underlying supporting documentation;
Challenging assumptions and judgements made by management in their significant accounting estimates;
Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.
IMAAN HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF IMAAN HEALTHCARE LIMITED
- 9 -
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Andrew Davis ACCA CTA MAAT (Senior Statutory Auditor)
For and on behalf of AMS Audit Limited, Statutory Auditor
Chartered Accountants
1 Hardman Street
Spinningfields
Manchester
M3 3HF
15 October 2026
IMAAN HEALTHCARE LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 28 OCTOBER 2025
- 10 -
2025
2024
Notes
£
£
Turnover
3
63,778,806
55,665,561
Cost of sales
(42,274,616)
(37,085,647)
Gross profit
21,504,190
18,579,914
Administrative expenses
(20,076,990)
(17,350,952)
Other operating income
153,962
209,238
Operating profit
4
1,581,162
1,438,200
Interest receivable and similar income
8
133,984
2,205
Interest payable and similar expenses
9
(32,642)
(50,921)
Amounts written off investments
10
(50,653)
(58,310)
Fair value gains and losses on investment properties
15
48,000
438,192
Profit before taxation
1,679,851
1,769,366
Tax on profit
11
(192,266)
(444,211)
Profit for the financial year
29
1,487,585
1,325,155
Profit for the financial year is attributable to:
- Owners of the parent company
1,228,702
1,210,029
- Non-controlling interests
258,883
115,126
1,487,585
1,325,155
Total comprehensive income for the year is attributable to:
- Owners of the parent company
1,228,702
1,210,029
- Non-controlling interests
258,883
115,126
1,487,585
1,325,155
The profit and loss account has been prepared on the basis that all operations are continuing operations.
IMAAN HEALTHCARE LIMITED
GROUP BALANCE SHEET
AS AT
28 OCTOBER 2025
28 October 2025
- 11 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
13
7,268,061
8,926,008
Other intangible assets
13
-
291
Total intangible assets
7,268,061
8,926,299
Tangible assets
14
6,315,383
5,153,759
Investment property
15
1,421,511
1,373,511
Investments
16
132,599
306
15,137,554
15,453,875
Current assets
Stocks
19
2,202,654
2,373,535
Debtors
21
16,597,816
12,490,616
Cash at bank and in hand
2,958,528
3,229,706
21,758,998
18,093,857
Creditors: amounts falling due within one year
22
(17,255,483)
(16,349,235)
Net current assets
4,503,515
1,744,622
Total assets less current liabilities
19,641,069
17,198,497
Creditors: amounts falling due after more than one year
23
(7,577,150)
(5,933,576)
Provisions for liabilities
Deferred tax liability
26
340,764
365,647
(340,764)
(365,647)
Net assets
11,723,155
10,899,274
Capital and reserves
Called up share capital
28
10,004
10,004
Profit and loss reserves
29
12,100,234
11,257,949
Equity attributable to owners of the parent company
12,110,238
11,267,953
Non-controlling interests
(387,083)
(368,679)
Total equity
11,723,155
10,899,274
IMAAN HEALTHCARE LIMITED
GROUP BALANCE SHEET (CONTINUED)
AS AT
28 OCTOBER 2025
28 October 2025
- 12 -
The financial statements were approved by the board of directors and authorised for issue on 15 October 2026 and are signed on its behalf by:
15 October 2026
Mr Z A Malik
Director
Company registration number 08105959 (England and Wales)
IMAAN HEALTHCARE LIMITED
COMPANY BALANCE SHEET
AS AT 28 OCTOBER 2025
28 October 2025
- 13 -
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
16
202
202
Current assets
Debtors
21
772,401
772,401
Net current assets
772,401
772,401
Total assets less current liabilities
772,603
772,603
Creditors: amounts falling due after more than one year
23
(668,293)
(668,293)
Net assets
104,310
104,310
Capital and reserves
Called up share capital
28
10,004
10,004
Profit and loss reserves
29
94,306
94,306
Total equity
104,310
104,310
As permitted by section 408 of the Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £484,103 (2024 - £118,132 loss).
These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.
The financial statements were approved by the board of directors and authorised for issue on 15 October 2026 and are signed on its behalf by:
15 October 2026
Mr Z A Malik
Director
Company registration number 08105959 (England and Wales)
IMAAN HEALTHCARE LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 28 OCTOBER 2025
- 14 -
Share capital
Profit and loss reserves
Total controlling interest
Non-controlling interest
Total
Notes
£
£
£
£
£
Balance at 29 October 2023
10,004
10,595,947
10,605,951
(212,827)
10,393,124
Year ended 28 October 2024:
Profit and total comprehensive income
-
1,210,029
1,210,029
115,126
1,325,155
Dividends
12
-
(548,027)
(548,027)
(270,978)
(819,005)
Balance at 28 October 2024
10,004
11,257,949
11,267,953
(368,679)
10,899,274
Year ended 28 October 2025:
Profit and total comprehensive income
-
1,228,702
1,228,702
258,883
1,487,585
Dividends
12
-
(386,417)
(386,417)
(277,287)
(663,704)
Balance at 28 October 2025
10,004
12,100,234
12,110,238
(387,083)
11,723,155
IMAAN HEALTHCARE LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 28 OCTOBER 2025
- 15 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 29 October 2023
10,004
212,438
222,442
Year ended 28 October 2024:
Loss and total comprehensive income for the year
(118,132)
(118,132)
Balance at 28 October 2024
10,004
94,306
104,310
Year ended 28 October 2025:
Profit and total comprehensive income
484,103
484,103
Dividends
12
(484,103)
(484,103)
Balance at 28 October 2025
10,004
94,306
104,310
IMAAN HEALTHCARE LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 28 OCTOBER 2025
- 16 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash (absorbed by)/generated from operations
34
(1,873,753)
4,972,287
Interest paid
(32,642)
(50,921)
Income taxes paid
(267,038)
(499,131)
Net cash (outflow)/inflow from operating activities
(2,173,433)
4,422,235
Investing activities
Purchase of intangible assets
(1,685,079)
(4,217,682)
Proceeds from disposal of intangibles
2,959,546
2,132,757
Purchase of tangible fixed assets
(1,808,931)
(1,998,630)
Proceeds from disposal of tangible fixed assets
240,000
344,586
Purchase of investments
(130)
(255)
Repayment of loans
1,787,665
(1,011,428)
Interest received
1,821
2,205
Other income received from investments
132,163
-
Net cash generated from/(used in) investing activities
1,627,055
(4,748,447)
Financing activities
Proceeds from borrowings
1,134,688
1,523,485
Repayment of borrowings
(168,832)
-
Repayment of bank loans
-
(29,888)
Payment of finance leases obligations
(26,952)
(26,544)
Dividends paid to equity shareholders
(386,417)
(548,027)
Dividends paid to non-controlling interests
(277,287)
(270,978)
Net cash generated from financing activities
275,200
648,048
Net (decrease)/increase in cash and cash equivalents
(271,178)
321,836
Cash and cash equivalents at beginning of year
3,229,706
2,907,870
Cash and cash equivalents at end of year
2,958,528
3,229,706
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 OCTOBER 2025
- 17 -
1
Accounting policies
Company information
Imaan Healthcare Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is Unit 2 Micklehead Business Park, St Michaels Road, Lea Green, St Helens, WA9 4YU.
The group consists of Imaan Healthcare Limited and all of its subsidiaries.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention other than investments properties that are held at fair value. The principal accounting policies adopted are set out below.
The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:
Section 4 ‘Statement of Financial Position’: Reconciliation of the opening and closing number of shares;
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;true
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues’true: Carrying amounts, interest income/expense and net gains/losses for each category of financial instrument; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’true: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’true: Compensation for key management personnel.
1.2
Business combinations
In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.
Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 18 -
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company Imaan Healthcare Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 28 October 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.
1.4
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the Group and Company have adequate resources to continue in operational existence for a period of at least twelve months from the date of approval of the financial statements.true
In reaching this conclusion, the directors have considered the Group's trading performance, current financial position, available banking facilities, projected cash flows and working capital requirements.
The directors have also considered wider economic conditions, including inflationary pressures and interest rate movements, and have reflected these factors within their forecasts and assessments.
The directors are satisfied that the Group and Company have adequate resources to continue in operational existence for the foreseeable future and accordingly continue to adopt the going concern basis of accounting in preparing the financial statements
1.5
Revenue
Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.
When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 19 -
1.6
Intangible fixed assets - goodwill
Goodwill arising on the acquisition of pharmacy businesses and pharmacy licences is capitalised and recognised as an intangible fixed asset.
Goodwill is initially measured as the excess of the cost of acquisition over the fair value of the identifiable net assets acquired. Following initial recognition, goodwill is carried at cost less accumulated amortisation and impairment losses.
The directors have assessed the useful economic life of acquired goodwill and pharmacy licences as between 5 and 10 years, reflecting the expected period over which economic benefits will be derived from the acquired pharmacies. Amortisation is charged on a straight-line basis over the estimated useful economic life.
The carrying value of goodwill and pharmacy licences is reviewed annually for indicators of impairment. Where indicators exist, or as part of the annual review process, the recoverable amount is estimated by reference to the profitability and cash-generating capacity of the underlying pharmacy operations. Where the recoverable amount is lower than the carrying amount, an impairment loss is recognised immediately in the profit and loss account.
1.7
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
Intangible assets comprise primarily lease premiums paid in advance for the use of the trading premises. Such assets are defined as having finite useful lives and the costs are amortised on a straight line basis over their estimated useful lives of 10 years. Intangible assets are stated at cost less amortisation and are reviewed for impairment whenever there is an indication that the carrying value may be impaired.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Lease premium
10 years
1.8
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:
Land and buildings Freehold
No depreciation
Land and buildings Leasehold
At varying rates on cost
Property improvements
5% straight line
Fixtures, fittings & equipment
25% reducing balance
Computer equipment
33% straight line
Motor vehicles
25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 20 -
1.9
Investment property
Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. Changes in fair value are recognised in profit or loss.
1.10
Fixed asset investments
Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.
In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.
A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Investments in associates are initially recognised at the transaction price (including transaction costs) and are subsequently adjusted to reflect the group’s share of the profit or loss, other comprehensive income and equity of the associate using the equity method. Any difference between the cost of acquisition and the share of the fair value of the net identifiable assets of the associate on acquisition is recognised as goodwill. Any unamortised balance of goodwill is included in the carrying value of the investment in associates.
Losses in excess of the carrying amount of an investment in an associate are recorded as a provision only when the company has incurred legal or constructive obligations or has made payments on behalf of the associate.
In the parent company financial statements, investments in associates are accounted for at cost less impairment.
Entities in which the group has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
1.11
Impairment of fixed assets
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 21 -
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.12
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.13
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.14
Financial instruments
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 22 -
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Derecognition of financial liabilities
Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.
1.15
Equity instruments
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
1.16
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 23 -
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.17
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.18
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.19
Leases
As lessee
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
1
Accounting policies
(Continued)
- 24 -
As lessor
When the group acts as a lessor, a lease is classified as a finance lease whenever it transfers substantially all the risks and rewards of ownership of the underlying asset to the lessee, either at the end of the lease term or for the major part of the economic life of the asset. All other leases are classified as operating leases. If an arrangement contains both lease and non-lease components, the group allocates the consideration in the contract to the two elements.
Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.
1.20
Subsidiary undertakings exempt from audit
Under Section 479a of the Companies Act 2006 available to subsidiary undertakings, the company provides a guarantee in respect of the below subsidiary undertakings claiming exemption from audit.
Slyne Healthcare Limited (08399442)
Imaan Limited (06415284)
Feraz Limited (07050590)
Penyffordd Pharmacy Limited (04329906)
Townfield Pharmacy Limited (04847565)
Hale Village Limited (04730742)
SJZ Limited (06788645)
Nuur Limited (06896612)
Broadheath Healthcare Limited (08086040)
Keswick Healthcare Limited (09177781)
Allestree Healthcare Ltd (12937123)
Liverpool Road Healthcare Ltd (12937848)
The Ridge Bradford Healthcare Limited (12326018)
London Road Healthcare Ltd (12258108)
Greenlife Clinical Services Ltd (11766715)
Leylands Lane Healthcare Ltd (12698503)
Peel St Healthcare Ltd (12257727)
Werneth Healthcare Ltd (12258493)
LP SD Twenty Two Ltd (14765274)
LP SD Twenty Three Ltd (14765295)
LP SD Twenty Four Ltd (14767307)
LP SD Twenty Five Ltd (14767311)
LP SD Twenty Nine Ltd (14817003)
LP SD Thirty One Ltd (14817143)
LP SD One Hundred Fourteen Ltd (15075071)
Guardian Street Healthcare Ltd (15929350)
Moorgate Imaan Healthcare Ltd (15930271)
Northeast Imaan Healthcare Ltd (15670780)
Tupton Healthcare Ltd (10312123)
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 25 -
2
Judgements and key sources of estimation uncertainty
In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.
Investment Property Valuation
The fair value of investment properties is based on property valuations by the directors which are derived from a number of assumptions and the general strength of the property market and the wider economy. Significant changes to any of these factors may affect the fair value of the properties either in a negative or positive manner. The directors are satisfied at the year end that the market value of the investment properties remains appropriate.
Deferred Taxation on Investment Property Valuation
In line with the requirements of FRS102, the revaluation of investment properties requires a corresponding deferred tax liability. This is an estimate of the expected tax liability on the sale of the properties. This is reviewed annually to ensure that it is at the effective tax rate expected at the date of sale.
Goodwill
The group hold a number of pharmacy licences. These are assessed to have a minimum expected useful economic life of 10 years. This is reviewed annually by the directors with an impairment review carried out via a value in use calculation. The value in use calculation requires the entity to estimate the future cash flows expected to arise from the cash generating unit and a suitable discount rate in order to calculate present value or the expected future value of these pharmacy licences. The carrying amount of goodwill in relation to these licences at the balance sheet date is £7,268,061 (2024 - £8,926,008) and no impairment was required to be recognised during the year.
Stock
The directors considers stock valuation to be a key source of estimation uncertainty. The Group uses third party experts, Retail & Asset Solutions Limited to count and value the stock at the year end. The value of stock is based on industry cost guidance less impairment. At 28 October 2025 the stock was valued at £2,202,654 (2024: £2,373,535).
Freehold land and buildings
The group owns freehold land and buildings which are carried at cost less any impairment. The directors have exercised judgement in determining that no depreciation is charged, as the residual value is considered to be not materially different from the carrying amount and any depreciation charge would therefore be immaterial. This judgement is reviewed annually, including consideration of the assets’ condition, expected useful economic lives, residual values and any indicators of impairment. No impairment has been identified in the year.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 26 -
3
Turnover and other revenue
An analysis of the group's turnover is as follows:
2025
2024
£
£
Turnover analysed by class of business
NHS Sales
58,173,446
52,119,173
Non NHS Sales
5,605,360
3,546,388
63,778,806
55,665,561
2025
2024
£
£
Turnover analysed by geographical market
UK
63,778,806
55,665,561
2025
2024
£
£
Other revenue
Interest income
1,821
2,205
Training grants
135,727
209,238
4
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging/(crediting):
Depreciation of tangible fixed assets
407,425
381,029
Profit on disposal of tangible fixed assets
(39,528)
(21,437)
Amortisation of intangible assets
1,036,546
1,175,514
Profit on disposal of intangible assets
(788,137)
(835,684)
Operating lease charges
1,031,973
919,413
5
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
40,000
25,000
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 27 -
6
Employees
The average monthly number of persons (including directors) employed by the group and company during the year was:
Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Directors
13
2
2
2
Administration
568
540
Total
581
542
2
2
Their aggregate remuneration comprised:
Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
8,960,776
7,826,688
Social security costs
814,890
454,376
-
-
Pension costs
148,657
123,379
9,924,323
8,404,443
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
25,140
25,140
Company pension contributions to defined contribution schemes
380
380
25,520
25,520
8
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
781
745
Other interest income
1,040
1,460
Total interest revenue
1,821
2,205
Income from fixed asset investments
Income from participating interests - associates
132,163
-
Total income
133,984
2,205
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 28 -
9
Interest payable and similar expenses
2025
2024
£
£
Interest on bank overdrafts and loans
-
407
Interest on finance leases and hire purchase contracts
1,894
17,088
Other interest
30,748
33,426
Total finance costs
32,642
50,921
10
Amounts written off investments
2025
2024
£
£
Amounts written off current loans
(50,653)
(58,310)
11
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
244,455
254,313
Adjustments in respect of prior periods
(18,725)
(539)
Total current tax
225,730
253,774
Deferred tax
Origination and reversal of timing differences
(33,464)
207,516
Adjustment in respect of prior periods
-
(17,079)
Total deferred tax
(33,464)
190,437
Total tax charge
192,266
444,211
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
11
Taxation
(Continued)
- 29 -
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
Profit before taxation
1,679,851
1,769,366
Expected tax charge based on the standard rate of corporation tax in the UK of 25% (2024: 25%)
419,963
442,342
Effects of:
Expenses that are not deductible in determining taxable profit
(8,844)
(66,116)
Income not taxable in determining taxable profit
(20,242)
16,596
Gains not taxable
(169,631)
(264,240)
Utilisation of tax losses not previously recognised
(166,038)
(14,661)
Unutilised tax losses carried forward
21,520
31,317
Adjustments in respect of prior years
(18,724)
(539)
Permanent capital allowances in excess of depreciation
134,262
251,270
Depreciation on assets not qualifying for tax allowances
-
(1,447)
Tax under/(over) provided in prior years
-
(17,079)
Tax on chargeable gains
-
66,768
Taxation charge in the financial statements
192,266
444,211
12
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Final paid
484,103
-
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 30 -
13
Intangible fixed assets
Group
Goodwill, patents and licences
Lease premium
Total
£
£
£
Cost
At 29 October 2024
11,831,855
4,333
11,836,188
Additions
1,685,079
-
1,685,079
Disposals
(2,965,302)
-
(2,965,302)
At 28 October 2025
10,551,632
4,333
10,555,965
Amortisation and impairment
At 29 October 2024
2,905,847
4,042
2,909,889
Amortisation charged for the year
1,036,255
291
1,036,546
Disposals
(658,531)
-
(658,531)
At 28 October 2025
3,283,571
4,333
3,287,904
Carrying amount
At 28 October 2025
7,268,061
-
7,268,061
At 28 October 2024
8,926,008
291
8,926,299
The company had no intangible fixed assets at 28 October 2025 or 28 October 2024.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 31 -
14
Tangible fixed assets
Group
Land and buildings Freehold
Land and buildings Leasehold
Property improvements
Fixtures, fittings & equipment
Computer equipment
Motor vehicles
Total
£
£
£
£
£
£
£
Cost
At 29 October 2024
3,637,700
426,386
121,178
1,527,352
90,776
734,623
6,538,015
Additions
1,293,959
-
-
446,674
8,088
60,210
1,808,931
Disposals
(193,701)
-
-
(103,162)
(285)
-
(297,148)
At 28 October 2025
4,737,958
426,386
121,178
1,870,864
98,579
794,833
8,049,798
Depreciation and impairment
At 29 October 2024
867
107,506
12,118
775,225
68,003
420,537
1,384,256
Depreciation charged in the year
-
5,223
6,059
288,101
14,467
93,575
407,425
Eliminated in respect of disposals
-
-
-
(57,076)
(190)
-
(57,266)
At 28 October 2025
867
112,729
18,177
1,006,250
82,280
514,112
1,734,415
Carrying amount
At 28 October 2025
4,737,091
313,657
103,001
864,614
16,299
280,721
6,315,383
At 28 October 2024
3,636,833
318,880
109,060
752,127
22,773
314,086
5,153,759
The company had no tangible fixed assets at 28 October 2025 or 28 October 2024.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
14
Tangible fixed assets
(Continued)
- 32 -
Included within tangible fixed assets are assets held under finance leases or hire purchase contracts, as follows:
Group
Company
2025
2024
2025
2024
£
£
£
£
Motor vehicles
51,765
69,020
15
Investment property
Group
Company
2025
2025
£
£
Fair value
At 29 October 2024 and 28 October 2025
1,373,511
Net gains or losses through fair value adjustments
48,000
-
At 28 October 2025
1,421,511
Investment property comprises property held by the business rented to third parties. The fair value of the investment property has been arrived at by the directors. The valuation was made on an open market value basis by reference to market evidence of transaction prices for similar properties.
16
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
17
-
-
202
202
Investments in associates
18
132,599
306
132,599
306
202
202
Movements in fixed asset investments
Group
Shares in associates
£
Cost or valuation
At 29 October 2024
306
Additions
132,293
At 28 October 2025
132,599
Carrying amount
At 28 October 2025
132,599
At 28 October 2024
306
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
16
Fixed asset investments
(Continued)
- 33 -
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 29 October 2024 and 28 October 2025
202
Carrying amount
At 28 October 2025
202
At 28 October 2024
202
17
Subsidiaries
Details of the company's subsidiaries at 28 October 2025 are as follows:
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
17
Subsidiaries
(Continued)
- 34 -
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Broadheath Healthcare Limited
UK
Ordinary
0
80.00
Feraz Limited
UK
Ordinary
0
100.00
Hale Village Limited
UK
Ordinary
0
100.00
Imaan Limited
UK
Ordinary
100.00
-
Keswick Healthcare Limited
UK
Ordinary
0
100.00
Nuur Limited
UK
Ordinary
0
100.00
Penyffordd Pharmacy Limited
UK
Ordinary
0
100.00
SJZ Limited
UK
Ordinary
0
90.00
Slyne Healthcare Limited
UK
Ordinary
0
65.00
Townfield Pharmacy Limited
UK
Ordinary
0
100.00
Allestree Healthcare Ltd
UK
Ordinary
0
80.00
Liverpool Road Healthcare Ltd
UK
Ordinary
0
80.00
The Ridge Bradford Healthcare Limited
UK
Ordinary
0
50.00
London Road Healthcare Ltd
UK
Ordinary
0
80.00
Greenlife Clinical Services Ltd
UK
Ordinary
0
75.00
Leylands Lane Healthcare limited
UK
Ordinary
0
80.00
Peel St Healthcare Ltd
UK
Ordinary
0
90.00
Werneth Healthcare Limited
UK
Ordinary
0
75.00
LP SD Thirty One Limited
UK
Ordinary
0
100.00
LP SD Twenty Five Limited
UK
Ordinary
0
100.00
LP SD Twenty Four Limited
UK
Ordinary
0
100.00
LP SD Twenty Nine Limited
UK
Ordinary
0
100.00
LP SD Twenty Three Limited
UK
Ordinary
0
100.00
LP SD Twenty Two Limited
UK
Ordinary
0
100.00
LP SD One Hundred Fourteen Ltd
UK
Ordinary
0
100.00
Guardian Street Healthcare Ltd
UK
Ordinary
0
100.00
Moorgate Imaan Healthcare Ltd
UK
Ordinary
0
100.00
Northeast Imaan Healthcare Ltd
UK
Ordinary
0
100.00
Tupton Healthcare Ltd
UK
Ordinary
0
100.00
Chelmsford Healthcare Ltd
UK
Ordinary
0
100.00
Hingmed Healthcare Ltd
UK
Ordinary
0
100.00
Marsh Road Healthcare Ltd
UK
Ordinary
0
100.00
N Bhatti Healthcare Ltd
UK
Ordinary
0
60.00
Selby Road Healthcare Ltd
UK
Ordinary
0
100.00
Shipley Pharma Ltd
UK
Ordinary
0
100.00
The investments in subsidiaries are all stated at cost but have been removed on consolidation. All subsidiaries have the same registered office as the parent company namely Unit 2 Micklehead Business Park, St Michaels Road, Lea Green, St Helens, WA9 4YU.
18
Associates
Details of associates at 28 October 2025 are as follows:
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
18
Associates
(Continued)
- 35 -
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Edgeley Healthcare Ltd
England and Wales
Ordinary shares
0
50
Fast Track Imaan Limited
England and Wales
Ordinary shares
0
50
Lower House Lane Limited
England and Wales
Ordinary shares
0
50
Station Road Healthcare Limited
England and Wales
Ordinary shares
0
50
Talbot Road Healthcare Limited
England and Wales
Ordinary shares
0
50
Walkley Road Healthcare Ltd
England and Wales
Ordinary shares
0
50
LP SD Thirty Limited
England and Wales
Ordinary shares
0
50
Dunchurch Pharma Ltd
England and Wales
Ordinary shares
0
50
Stanton Pharma Ltd
England and Wales
Ordinary shares
0
30
The investments in associates have all been accounted for in accordance with the equity method.
All associate undertakings have the same registered office as the parent company except Stanton Pharma Ltd which has a registered office at Bay 5 875 Tyburn Road, Birmingham, England, B24 9NY.
19
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Finished goods and goods for resale
2,202,654
2,373,535
20
Financial instruments
Group
Company
2025
2024
2025
2024
£
£
£
£
Carrying amount of financial assets
Debt instruments measured at amortised cost
14,751,211
11,546,606
n/a
n/a
Carrying amount of financial liabilities
Measured at amortised cost
23,984,116
21,505,081
n/a
n/a
21
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
6,383,659
6,445,314
Amounts owed by group undertakings
-
-
772,397
772,397
Amounts owed by undertakings in which the company has a participating interest
608,742
-
Other debtors
8,892,666
5,595,560
4
4
Prepayments and accrued income
712,749
449,742
16,597,816
12,490,616
772,401
772,401
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 36 -
22
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Obligations under finance leases
25
6,264
26,952
Trade creditors
14,159,832
13,271,585
Corporation tax payable
582,375
632,264
Other taxation and social security
266,142
145,466
Other creditors
1,413,387
1,942,437
Accruals and deferred income
827,483
330,531
17,255,483
16,349,235
23
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Obligations under finance leases
25
-
6,264
Other borrowings
24
6,893,168
5,927,312
668,293
668,293
Other creditors
683,982
-
7,577,150
5,933,576
668,293
668,293
24
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Loans from related parties
3,508,392
2,388,802
Other loans
3,384,776
3,538,510
668,293
668,293
6,893,168
5,927,312
668,293
668,293
Payable after one year
6,893,168
5,927,312
668,293
668,293
The other loans are due for full repayment in 2028, and interest is charged at a rate of 0.68% per month on the amount outstanding.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 37 -
25
Finance lease obligations
Group
Company
2025
2024
2025
2024
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
6,264
18,793
In two to five years
-
14,423
6,264
33,216
Finance lease payments represent rentals payable by the company or group for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.
26
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the group and company:
Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
340,764
365,647
The company has no deferred tax assets or liabilities.
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 29 October 2024
365,647
Credit to profit or loss
(33,464)
-
Other
8,581
-
Liability at 28 October 2025
340,764
The deferred tax liability set out above is expected to reverse within the foreseeable future and relates to the depreciation charged in excess of capital allowances claimed. The movement in the year comprises amounts recognised in profit or loss and other movements, including those arising on business combinations, as disclosed above.
27
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
148,657
123,379
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
27
Retirement benefit schemes
(Continued)
- 38 -
A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
28
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A of 1p each
988,600
988,600
9,886
9,886
Ordinary B of 1p each
10,000
10,000
100
100
Ordinary C of £1 each
1
1
1
1
Ordinary D of £1 each
1
1
1
1
Ordinary E of £1 each
1
1
1
1
Ordinary F of £1 each
1
1
1
1
Ordinary G of £1 each
1
1
1
1
Ordinary H of £1 each
1
1
1
1
Ordinary I of £1 each
1
1
1
1
Ordinary J of £1 each
1
1
1
1
Ordinary K of £1 each
1
1
1
1
Ordinary L of £1 each
1
1
1
1
Ordinary M of £1 each
1
1
1
1
Ordinary N of £1 each
1
1
1
1
Ordinary O of £1 each
1
1
1
1
Ordinary P of £1 each
1
1
1
1
Ordinary Q of £1 each
1
1
1
1
Ordinary R of £1 each
1
1
1
1
Ordinary S of £1 each
1
1
1
1
Ordinary T of £1 each
1
1
1
1
998,618
998,618
10,004
10,004
The Ordinary A and Ordinary B shares have full voting, dividend and capital rights. The Ordinary C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T shares have no right to receive notice of, or attend and vote at general meetings. On a winding up, only carry the right to receive the par value of the shares, treated as a separate class for dividends.
29
Reserves
Profit and loss reserves
Profit and loss reserves include the accumulated profit of the group in addition to the non-distributable fair value reserve in respect of the investment property held by the group.
30
Operating lease commitments
As lessee
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
30
Operating lease commitments
(Continued)
- 39 -
At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
Group
Company
2025
2024
2025
2024
£
£
£
£
Within 1 year
408,125
408,125
Years 2-5
65,451
454,576
473,576
862,701
31
Related party transactions
Remuneration of key management personnel
The remuneration of key management personnel is as follows.
2025
2024
£
£
Aggregate compensation
63,621
-
Transactions with related parties
During the year the group entered into the following transactions with related parties:
Purchases
Purchases
2025
2024
£
£
Group
Other related parties
878,750
-
The following amounts were outstanding at the reporting end date:
Amounts due to related parties
2025
2024
£
£
Group
Entities over which the group has control, joint control or significant influence
1,068,730
-
Other related parties
3,574,443
2,538,452
The above balances are interest free, unsecured and repayable on demand.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
31
Related party transactions
(Continued)
- 40 -
The following amounts were outstanding at the reporting end date:
Amounts due from related parties
2025
2024
Balance
Balance
£
£
Group
Entities over which the group has control, joint control or significant influence
1,599,515
-
Other related parties
4,757,059
3,777,994
Other information
Amounts due from and to related parties are owed from companies which have common directorship or common shareholding. These amounts are interest free, with no security and are repayable on demand.
The group has taken advantage of FRS 102, section 33.1A available to groups producing consolidated group financial statements and transactions with wholly owned subsidiaries, and has chosen not to disclose related party transactions within the group.
32
Directors' transactions
At the beginning of the year, a balance of £701,882 was owed by Imaan Healthcare Limited to Z Malik. During the year,the balance owed to director Z Malik increased by £801,292 through net payments. No dividends have been declared in respect of this shareholder.
At the beginning of the year, a balance of £837,799 was owed to Imaan Healthcare Limited from T Malik. During the year During the year, the director withdrew a total of £959,858 from the company and amounts totalling £1,797,657 were cleared. The maximum amount overdrawn during the year was £1,721,567. No dividends have been declared in respect of this shareholder.
Advances or credits have been granted by the group to its directors as follows:
Loans
% Rate
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
Mr Z A Malik -
-
(701,882)
-
(801,292)
(1,503,174)
Mr T Malik -
-
837,799
959,858
(1,797,657)
-
135,917
959,858
(2,598,949)
(1,503,174)
33
Controlling party
No individual shareholder controlled the company during the current and preceding period.
IMAAN HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 OCTOBER 2025
- 41 -
34
Cash (absorbed by)/generated from group operations
2025
2024
£
£
Profit after taxation
1,487,585
1,325,155
Adjustments for:
Taxation charged
192,266
444,211
Finance costs
32,642
50,921
Investment income
(133,984)
(2,205)
Gain on disposal of tangible fixed assets
(39,528)
(21,437)
Gain on disposal of intangible assets
(788,137)
(835,684)
Fair value gain on investment properties
(48,000)
(438,192)
Amortisation and impairment of intangible assets
1,036,546
1,175,514
Depreciation and impairment of tangible fixed assets
407,425
381,029
Other gains and losses
50,653
58,310
Movements in working capital:
Decrease/(increase) in stocks
170,881
(121,421)
Increase in debtors
(5,820,851)
(812,689)
Increase in creditors
1,578,749
3,768,775
Cash (absorbed by)/generated from operations
(1,873,753)
4,972,287
35
Analysis of changes in net debt - group
29 October 2024
Cash flows
28 October 2025
£
£
£
Cash at bank and in hand
3,229,706
(271,178)
2,958,528
Borrowings excluding overdrafts
(5,927,312)
(965,856)
(6,893,168)
Payment of finance leases obligations
(33,216)
26,952
(6,264)
(2,730,822)
(1,210,082)
(3,940,904)
2025-10-282024-10-29falsefalseCCH SoftwareCCH Accounts Production 2026.100Mr Z A MalikMr T Malikfalse08105959bus:Consolidated2024-10-292025-10-28081059592024-10-292025-10-28081059592025-10-2808105959bus:Director12024-10-292025-10-2808105959bus:Director22024-10-292025-10-2808105959bus:RegisteredOffice2024-10-292025-10-2808105959bus:Consolidated2025-10-28081059592024-10-2808105959core:Non-currentFinancialInstrumentscore:AfterOneYear2025-10-2808105959core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-2808105959core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-2808105959core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-2808105959core:ShareCapital2025-10-2808105959core:ShareCapital2024-10-2808105959core:RetainedEarningsAccumulatedLosses2025-10-2808105959core:RetainedEarningsAccumulatedLosses2024-10-2808105959core:ShareCapital2023-10-2808105959core:RetainedEarningsAccumulatedLosses2023-10-28081059592023-10-2808105959core:ShareCapital2023-10-292024-10-2808105959core:RetainedEarningsAccumulatedLosses2023-10-292024-10-28081059592023-10-292024-10-2808105959core:ShareCapital2024-10-292025-10-2808105959core:RetainedEarningsAccumulatedLosses2024-10-292025-10-2808105959core:Goodwill2024-10-292025-10-2808105959core:IntangibleAssetsOtherThanGoodwill2024-10-292025-10-2808105959core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-10-292025-10-2808105959core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-292025-10-2808105959core:LandBuildingscore:LongLeaseholdAssets2024-10-292025-10-2808105959core:LeaseholdImprovements2024-10-292025-10-2808105959core:FurnitureFittings2024-10-292025-10-2808105959core:ComputerEquipment2024-10-292025-10-2808105959core:MotorVehicles2024-10-292025-10-280810595912024-10-292025-10-2808105959core:MotorVehicles2025-10-2808105959core:MotorVehicles2024-10-2808105959dpl:Item22024-10-292025-10-2808105959core:Cost2025-10-2808105959core:Subsidiary12024-10-292025-10-2808105959core:Subsidiary22024-10-292025-10-2808105959core:Subsidiary32024-10-292025-10-2808105959core:Subsidiary42024-10-292025-10-2808105959core:Subsidiary52024-10-292025-10-2808105959core:Subsidiary62024-10-292025-10-2808105959core:Subsidiary72024-10-292025-10-2808105959core:Subsidiary82024-10-292025-10-2808105959core:Subsidiary92024-10-292025-10-2808105959core:Subsidiary102024-10-292025-10-2808105959core:Subsidiary112024-10-292025-10-2808105959core:Subsidiary122024-10-292025-10-2808105959core:Subsidiary132024-10-292025-10-2808105959core:Subsidiary142024-10-292025-10-2808105959core:Subsidiary152024-10-292025-10-2808105959core:Subsidiary162024-10-292025-10-2808105959core:Subsidiary172024-10-292025-10-2808105959core:Subsidiary182024-10-292025-10-2808105959core:Subsidiary192024-10-292025-10-2808105959core:Subsidiary202024-10-292025-10-2808105959core:Subsidiary212024-10-292025-10-2808105959core:Subsidiary222024-10-292025-10-2808105959core:Subsidiary232024-10-292025-10-2808105959core:Subsidiary242024-10-292025-10-2808105959core:Subsidiary252024-10-292025-10-2808105959core:Subsidiary262024-10-292025-10-2808105959core:Subsidiary272024-10-292025-10-2808105959core:Subsidiary282024-10-292025-10-2808105959core:Subsidiary292024-10-292025-10-2808105959core:Subsidiary302024-10-292025-10-2808105959core:Subsidiary312024-10-292025-10-2808105959core:Subsidiary322024-10-292025-10-2808105959core:Subsidiary332024-10-292025-10-2808105959core:Subsidiary342024-10-292025-10-2808105959core:Subsidiary352024-10-292025-10-2808105959core:Subsidiary112024-10-292025-10-2808105959core:Subsidiary222024-10-292025-10-2808105959core:Subsidiary332024-10-292025-10-2808105959core:Subsidiary442024-10-292025-10-2808105959core:Subsidiary552024-10-292025-10-2808105959core:Subsidiary662024-10-292025-10-2808105959core:Subsidiary772024-10-292025-10-2808105959core:Subsidiary882024-10-292025-10-2808105959core:Subsidiary992024-10-292025-10-2808105959core:Subsidiary10102024-10-292025-10-2808105959core:Subsidiary11112024-10-292025-10-2808105959core:Subsidiary12122024-10-292025-10-2808105959core:Subsidiary13132024-10-292025-10-2808105959core:Subsidiary14142024-10-292025-10-2808105959core:Subsidiary15152024-10-292025-10-2808105959core:Subsidiary16162024-10-292025-10-2808105959core:Subsidiary17172024-10-292025-10-2808105959core:Subsidiary18182024-10-292025-10-2808105959core:Subsidiary19192024-10-292025-10-2808105959core:Subsidiary20202024-10-292025-10-2808105959core:Subsidiary21212024-10-292025-10-2808105959core:Subsidiary22222024-10-292025-10-2808105959core:Subsidiary23232024-10-292025-10-2808105959core:Subsidiary24242024-10-292025-10-2808105959core:Subsidiary25252024-10-292025-10-2808105959core:Subsidiary26262024-10-292025-10-2808105959core:Subsidiary27272024-10-292025-10-2808105959core:Subsidiary28282024-10-292025-10-2808105959core:Subsidiary29292024-10-292025-10-2808105959core:Subsidiary30302024-10-292025-10-2808105959core:Subsidiary31312024-10-292025-10-2808105959core:Subsidiary32322024-10-292025-10-2808105959core:Subsidiary33332024-10-292025-10-2808105959core:Subsidiary34342024-10-292025-10-2808105959core:Subsidiary35352024-10-292025-10-2808105959core:Associate12024-10-292025-10-2808105959core:Associate22024-10-292025-10-2808105959core:Associate32024-10-292025-10-2808105959core:Associate42024-10-292025-10-2808105959core:Associate52024-10-292025-10-2808105959core:Associate62024-10-292025-10-2808105959core:Associate72024-10-292025-10-2808105959core:Associate82024-10-292025-10-2808105959core:Associate92024-10-292025-10-2808105959core:Associate112024-10-292025-10-2808105959core:Associate222024-10-292025-10-2808105959core:Associate332024-10-292025-10-2808105959core:Associate442024-10-292025-10-2808105959core:Associate552024-10-292025-10-2808105959core:Associate662024-10-292025-10-2808105959core:Associate772024-10-292025-10-2808105959core:Associate882024-10-292025-10-2808105959core:Associate992024-10-292025-10-2808105959core:CurrentFinancialInstruments2025-10-2808105959core:CurrentFinancialInstruments2024-10-2808105959core:CurrentFinancialInstruments12025-10-2808105959core:CurrentFinancialInstruments12024-10-2808105959core:Non-currentFinancialInstruments2025-10-2808105959core:Non-currentFinancialInstruments2024-10-2808105959core:Non-currentFinancialInstrumentscore:AfterOneYear12025-10-2808105959core:Non-currentFinancialInstrumentscore:AfterOneYear12024-10-2808105959core:WithinOneYear2025-10-2808105959core:WithinOneYear2024-10-2808105959core:BetweenTwoFiveYears2025-10-2808105959core:BetweenTwoFiveYears2024-10-2808105959core:WithinOneYearOverTime2024-10-292025-10-2808105959core:WithinOneYearOverTime2023-10-292024-10-2808105959core:BetweenTwoFiveYearsOverTime2024-10-292025-10-2808105959core:BetweenTwoFiveYearsOverTime2023-10-292024-10-2808105959bus:PrivateLimitedCompanyLtd2024-10-292025-10-2808105959bus:FRS1022024-10-292025-10-2808105959bus:Audited2024-10-292025-10-2808105959bus:ConsolidatedGroupCompanyAccounts2024-10-292025-10-2808105959bus:FullAccounts2024-10-292025-10-28xbrli:purexbrli:sharesiso4217:GBP